Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594226 | 0.80 | KCNH2 (0.79) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL15920946 | 0.79 | KCNH2 (0.83) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL27695348 | 0.79 | KCNH2 (0.83) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL155128 | 0.78 | SIGMAR1 (0.79) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL15690402 | 0.75 | KCNH2 (0.70) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL3453669 | 0.74 | DRD2 (1.00) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL27822324 | 0.72 | SIGMAR1 (0.64) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| Hexane SCHEMBL28857999 | 0.71 | DRD2 (0.56) | SIGMAR1DRD2CHRNA7KCNH2 | |
| SCHEMBL7442901 | 0.71 | ADRA2A (0.48) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 | |
| SCHEMBL1101883 | 0.70 | CHRNA7 (1.00) | SIGMAR1DRD2CHRNA7KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046561-B1 | COMPOUNDS FOR TREATING PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2023-02-22 | — | — | EP | disclosed |
| US-6544996-B2 | A substituted or unsubstituted phenyl-(4-trans-2-phenylcyclopropyl)methylpiperazine compounds or salt useful for treating brain disorders such as schizophrenia, Parkinson, dementia, depression and anxiety | NEUROGEN CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020022630-A1 | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands | NEUROGEN CORPORATION | 2002-02-21 | — | — | US | disclosed |
| US-6284761-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6284761-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022630-A1 | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands | DRD2, DRD4, PARK7 | SIGMAR1 57/4885DRD2 1/4885CHRNA7 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.